In adult patients with CKD associated with T2D
KERENDIA is the first and only MRA indicated to reduce the risk of1:
- Sustained eGFR decline
- End-stage kidney disease
- CV death
- Non-fatal MI
- Hospitalization for heart failure
CKD=chronic kidney disease; CV=cardiovascular; eGFR=estimated glomerular filtration rate; MI=myocardial infarction; MRA=mineralocorticoid receptor antagonist; T2D=type 2 diabetes.